The present invention relates to a hepcidin antagonist for use in the treatment of inflammatory diseases. TLR4-dependant intestinal hepcidin induces neutrophil migration and intestinal inflammation, and are expressed by lipopolysaccharides. The hepcidin is a proinflammatory molecule in macrophages which demonstrated its interest in inflammatory bowel diseases (IBDs).